title: Monoclonal immunoglobulin A antibodies directed against cholera toxin prevent the toxin-induced chloride secretory response and block toxin binding to intestinal epithelial cells in vitro.
abstract: Secretory immunoglobulin A (IgA) antibodies directed against cholera toxin (CT) are thought to be important in resistance to oral challenge with virulent Vibrio cholerae, although alternative mechanisms for protection of intestinal epithelia against CT-induced fluid secretion have been proposed. The ability of anti-CT IgA to block the effects of CT on human enterocytes has not been directly tested because of the lack of a well-defined in vitro intestinal epithelial cell system to directly measure toxin action and the limited availability of purified anti-CT IgA antibodies. We have generated hybridomas that produce monoclonal IgA and IgG antibodies directed against CT by fusion of Peyer's patch cells with mouse myeloma cells after oral-systemic immunization of mice with CT and CT B-subunit protein. All of the anti-CT antibodies recognized the B subunit. Three clones (designated anti-CTB IgA-1, IgA-2, and IgA-3) which produced IgA antibodies in dimeric and polymeric forms were selected. Checkerboard immunoblotting demonstrated that IgA-1 recognized an epitope distinct from that recognized by IgA-2 and IgA-3 and that none of the antibodies were directed against the binding site of GM1, the intestinal cell membrane toxin receptor. The protective capacity of these IgAs was tested in vitro with human T84 colon carcinoma cells grown on permeable supports as confluent monolayers of polarized enterocytes. When each anti-CTB IgA was mixed with 10 nM CT and applied to the apical surfaces of T84 cell monolayers, all three IgAs blocked CT-induced Cl- secretion in a dose-dependent manner and completely inhibited binding of rhodamine-labelled CT to apical cell membranes. Thus, monoclonal anti-CTB IgA antibodies are sufficient to protect human enterocytes in vitro against CT binding and action.
authors.affiliation: GI Cell Biology Laboratory, Children's Hospital, Boston, Massachusetts.
authors.forename: F M
authors.initials: FM
authors.lastname: Apter
authors.forename: W I
authors.initials: WI
authors.lastname: Lencer
authors.forename: R A
authors.initials: RA
authors.lastname: Finkelstein
authors.forename: J J
authors.initials: JJ
authors.lastname: Mekalanos
authors.forename: M R
authors.initials: MR
authors.lastname: Neutra
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001665:Binding Sites; D002460:Cell Line; D002712:Chlorides / Q000378:metabolism*; D002771:Cholera / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D002772:Cholera Toxin / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000633:toxicity*; D004848:Epithelium / Q000187:drug effects / Q000378:metabolism; D000939:Epitopes; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D007070:Immunoglobulin A / Q000494:pharmacology; D007421:Intestine, Small / Q000187:drug effects* / Q000378:metabolism; D051379:Mice; D014734:Vibrio cholerae / Q000276:immunology* / Q000472:pathogenicity
chemical_list: D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D002712:Chlorides; D000939:Epitopes; D007070:Immunoglobulin A; D002772:Cholera Toxin